The global clinical trials matching software market size is expected to reach USD 396.1 million by 2030, based on a new report by Grand View Research, Inc. It is expected to expand at a CAGR of 13.2% from 2023 to 2030. The significant increase in the number of ongoing clinical trials is likely to drive the market. In addition, the growing adoption of the clinical trial matching software catering to the clinical trials, along with the increased demand for virtual trials and automation in the healthcare sector are some of the key factors contributing to the market growth. The matching software help in effective and fast patient matching with patient-centric approaches.
In clinical trials, patient recruitment or matching can be time-consuming, and finding the right match can be a hurdle. Screening or locating prospective respondents who are qualified, considering all elements of the trials, verifying awareness, and getting informed consent to participate are the factors taken into consideration while recruiting patients. Enlisting the individuals in accordance with the qualifying requirements is crucial, hence the trial matching technology has been proved to be useful, especially in the COVID-19 scenario.
The software helps not only to find the right match but also saves the R&D-related costs, enabling smoother operations without human intervention. The software providers are introducing new innovative techniques to strengthen their market position. For instance, in February 2022, the CTMA expanded CT-SCOUT technology offering in rheumatology.
Request a free sample copy or view report summary: Clinical Trials Matching Software Market Report
Based on deployment mode, the web and cloud based segment dominated the market in terms of revenue in 2022 and it is expected to register the fastest CAGR during the forecast period. The cloud computing models operate with no maintenance or upkeep charges and customers only have to pay for the services that are used. On the other hand, on-premises deployment involves in-house infrastructure, in-house IT support, working capital, and higher integration costs. Hence, web and cloud based models are preferred
Based on end use, pharmaceuticals and biotechnology companies captured the largest revenue share in 2022 owing to the higher adoption of software during ongoing clinical studies for cost-saving in the R&D activities
The CROs end-use segment is anticipated to expand at the fastest CAGR of 13.7% during the forecast period. CROs provide the professional assistance, expertise, and execution experience required for clinical trials quickly, without the need for the sponsor to engage such people full-time. CROs are preferred for outsourcing as their services are cost and time-effective
In 2022, North America led the market in terms of revenue owing to the rising adoption of the clinical trial matching software by the pharma, biotech, and medical companies in the region
Asia Pacific is anticipated to register the fastest growth rate over the forecast period due to the availability of a large patient pool supporting easy recruitment of patients/candidates
Grand View Research has segmented the global clinical trials matching software market based on deployment mode, end use, and region:
Clinical Trials Matching Software Deployment Mode Outlook (Revenue, USD Million, 2018 - 2030)
Web & Cloud-based
On-premise
Clinical Trials Matching Software End-use Outlook (Revenue, USD Million, 2018 - 2030
Pharmaceutical & Biotechnology Companies
CROs
Medical Device Firms
Clinical Trials Matching Software Regional Outlook (Revenue, USD Million, 2018 - 2030)
North America
U.S.
Canada
Europe
UK
Germany
France
Italy
Spain
Sweden
Norway
Denmark
Asia Pacific
China
Japan
India
Australia
Thailand
South Korea
Latin America
Brazil
Mexico
Argentina
Middle East and Africa
Saudi Arabia
South Africa
UAE
Kuwait
List of Key Players of Clinical Trials Matching Software Market
IBM Clinical development
Antidote Technologies, Inc.
Clinical Trials Mobile Application
SSS International Clinical Research
Advarra
Aris Global
"The quality of research they have done for us has been excellent..."